Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last C$11.41 CAD
Change Today +0.16 / 1.42%
Volume 5.6K
As of 3:59 PM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

cardiome pharma corp (COM) Snapshot

Previous Close
Day High
Day Low
52 Week High
01/21/15 - C$13.80
52 Week Low
08/6/14 - C$6.62
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CARDIOME PHARMA CORP (COM)

Related News

No related news articles were found.

cardiome pharma corp (COM) Related Businessweek News

No Related Businessweek News Found

cardiome pharma corp (COM) Details

Cardiome Pharma Corp., a specialty pharmaceutical company, engages in the development and commercialization of cardiovascular therapies that enhance the life and health of patients from heart diseases. It offers BRINAVESS (vernakalant IV) for the conversion of recent onset atrial fibrillation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in acute coronary syndrome patients. It has operations in Canada, the United States, and Europe. The company was formerly known as Nortran Pharmaceuticals Inc. and changed its name to Cardiome Pharma Corp. in June 2001. Cardiome Pharma Corp. was founded in 1986 and is based in Vancouver, Canada.

Founded in 1986

cardiome pharma corp (COM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: C$508.3K
Chief Financial Officer
Total Annual Compensation: C$250.2K
Chief Operating Officer
Total Annual Compensation: C$220.3K
Corporate General Counsel
Total Annual Compensation: C$206.0K
Compensation as of Fiscal Year 2013.

cardiome pharma corp (COM) Key Developments

Cardiome Pharma Corp. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Cardiome Pharma Corp. reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net loss of $3.9 million or $0.23 per share compared to a net loss of $3.1 million or $0.20 per share for the three months ended March 31, 2014. Revenue was $5.5 million, compared to $7.6 million a year ago. The decrease was due primarily to foreign exchange, timing of distributor sales, and a decrease in AGGRASTAT® sales due to generic competition. Operating loss was $2.657 million against $2.681 million a year ago. Loss before income taxes was $3.780 million against $3.017 million a year ago. Net cash used in operating activities was $3.168 million against $9.294 million a year ago. Purchase of property and equipment were $0.89 million against $0.3 million a year ago. Increase in intangible assets was $0.13 million against $0.12 million a year ago.

Cardiome and AOP Orphan Pharma Enter ESMOCARD Commercialization Agreement

Cardiome Pharma Corp. announced that the company has entered a commercialization agreement with AOP Orphan Pharma to sell AOP's cardiovascular products, ESMOCARD® and ESMOCARD LYO® (esmolol hydrochloride) in Italy, France, Spain and Belgium. Financial details of the agreement were not disclosed.

Cardiome Pharma Corp. to Report Q1, 2015 Results on May 13, 2015

Cardiome Pharma Corp. announced that they will report Q1, 2015 results at 8:00 AM, US Eastern Standard Time on May 13, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
COM:CN C$11.41 CAD +0.16

COM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Eli Lilly & Co $74.31 USD +0.01
Medicure Inc C$2.40 CAD +0.04
Merck & Co Inc $58.97 USD -0.41
Medicines Co/The $27.11 USD +0.02
View Industry Companies

Industry Analysis


Industry Average

Valuation COM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 5.2x
Price/Book 10.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 4.4x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CARDIOME PHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at